Company
PharmaDrug Inc
CNSX:BUZZ
PharmaDrug Inc is a specialty pharmaceutical company focused on the research, development and commercialization of controlled substances and natural medicines such as psychedelics and previously approved drugs. The company owns 51% of Sairiyo Therapeutics, a biotech company specialising in researching and reformulating established natural medicines to bring them through clinical trials and the associated regulatory approval process in the US and Europe.
66 stories
PharmaDrug wraps up key step in production of oral bioavailable version of its oncology and infectious disease drug cepharanthine
Completion of this lot advances the company's efforts to support pre-clinical and clinical development, including the commencement of Phase 2 clinical studies, for parallel indications in oncology and infectious disease
PharmaDrug aims to file provisional patent for treatment of glaucoma in the fourth quarter this year
The firm said it has selected a final lead drug candidate from a short list of six DMT analogues and intends to submit the patent in the fourth quarter this year
PharmaDrug completes significant groundwork to support multi-kilogram production of cepharanthine-2HCL drug
PharmaDrug intends to develop and commercialize PD-001 as an oral antiviral treatment for mild to moderate SARS-CoV-2 infections, plus esophageal and prostate cancers
PharmaDrug closes sale of German cannabis assets to Khiron Life Sciences
With the sale of its German asset complete, PharmaDrug said it continues to advance PD-001, its patented version of cepharanthine, towards potential FDA clinical trials on both the oncology and antiviral fronts
PharmaDrug announces non-brokered offering of $650,000 of convertible secured debentures and issuance of shares
The company said each debenture bears interest at a rate of 15% per annum payable monthly in arrears and it matures one year from the date of issue and is convertible into common shares at a price of $0.05
PharmaDrug unveils positive findings of study of cepharanthine (PD-001) candidate to treat esophageal cancer
"This study outcome serves to further support our goal of moving towards an FDA clinical trial and will provide the company with the opportunity to fully leverage the benefits of the previously granted FDA orphan drug designation for cephar
PharmaDrug agrees to sell German cannabis distribution subsidiary in exchange for equity in Khiron Life Sciences and $1.1M promissory note
Pharmadrug Production has a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the European Union
PharmaDrug closes first tranche of a non-brokered private placement for aggregate gross proceeds of $280,000
The company said it intends to use the net proceeds from the offering to assist in the production of pharmaceutical-grade cepharanthine to be used in Phase I and Phase II clinical trials and for general working capital
PharmaDrug advances its glaucoma research program with selection of lead DMT analog
The company said that the lead candidate was chosen because it displayed superior potency and a favourable toxicity profile
PharmaDrug files provisional patent following positive findings for PD-001 and frontline chemotherapy combo in prostate cancer study
The Canadian company said the provisional patent was filed on April 14, 2022, to support the use of PD-001 plus cabazitaxel for primary, metastatic, and chemotherapy-resistant prostate cancer
PharmaDrug advances DMT-analogue glaucoma program with fabrication of medical device to lower intraocular pressure
The company said a head-to-head drug elution study of its three undisclosed DMT-analogue candidates has now been completed while supportive cell-based biocompatibility has been examined
PharmaDrug advances PD-001, its improved version of cepharanthine to treat cancer and infectious disease
PharmaDrug believes the FDA feedback it has received provides a path to agreements on IND-enabling studies, the design of a Phase 1/2 clinical study, and the overall clinical development plan to move PD-001 forward as an oral treatment for
PharmaDrug reports interim positive findings for combination of cepharanthine and frontline chemotherapy for IND-enabling prostate cancer study
The company reported that a once-per-day oral regimen of PD-001, in combination with cabazitaxel provided statistically significant benefit at the scheduled end of dosing in its ongoing prostate efficacy study
PharmaDrug announces positive results from DMT-analogue program to treat glaucoma
Following this successful outcome, the company, in collaboration with the Terasaki Institute for Biomedical Innovation (TIBI), has initiated fabrication activities necessary to produce a novel medical device capable of delivering sustained,
PharmaDrug submits US provisional patent application for cepharanthine to treat prostate cancer
“While esophageal cancer continues to be our main focus with a goal to move towards an FDA clinical trial, we believe that cepharanthine will ultimately show a wider potential use in the treatment of cancers, specifically in combination wit
PharmaDrug initiates manufacturing of PD-001 for clinical programs in rare cancers and COVID-19
Parallel development of PD-001 for oncology and infectious disease indications will provide valuable time and cost efficiencies to the company by way of eliminating the need to duplicate multiple standard activities
PharmaDrug appoints Cindy Hutnik to its scientific and clinical advisory board
Hutnik will assist the company in its ongoing efforts to develop N,N-dimethyltryptamine (DMT) as a potential treatment for glaucoma
PharmaDrug looking to develop and commercialise a range of psychedelics, cannabis and naturally-derived drugs
The company owns 80% of Pharmadrug GmbH, a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification and 100% of Super Smart, a Dutch company building a modern adult-use psychedel
PharmaDrug aims to start clinical studies using cepharanthine for coronavirus in the second half of next year
The US Food & Drug Administration (FDA) has provided written responses which Pharmadrug believes provide "a path to agreements on IND-enabling studies, the design of a Phase 1/2 clinical study, and the overall clinical development plan to m
PharmaDrug announces positive results for preclinical study, initiates IND-enabling research for cepharanthine for several cancer treatments
The company said that it is now focusing on advancing IND-enabling studies to support future FDA clinical studies in 2022 for cepharanthine (PD-001)
PharmaDrug commissions TIBI for advancing psychedelics program with analogue DMT formulation to cure eye diseases
The Toronto-based company said that it will be focusing on comparing the potency of two candidate tryptamines, which were narrowed from an initial list of six
PharmaDrug boosts its product portfolio ahead of anticipated legalization of cannabis in Germany
While there are remaining differences in opinion about classification and sales channels, PharmaDrug believes cannabis will likely become legal within the near term as a controlled substance with expanded access.
PharmaDrug says its stock is now trading on OTCQB Venture Market in the US
The company believes the strategy to increase US investor ownership fits well with its growing focus on biotech research and development
PharmaDrug hails pre-clinical results on Cepharanthin to treat cancer; eying FDA IND-enabling animal studies in 4Q
The studies will examine the efficacy of cepharanthine on its own and when it is combined with standard-of care chemotherapy to support Phase 1 and 2 human clinical trials.
PharmaDrug gets pre-IND meeting request granted by US FDA for oral antiviral drug Cepharanthine to potentially treat coronavirus
CEO Daniel Cohen said 'forthcoming feedback from the FDA' will provide 'critical information relevant to defining our parallel development paths for PharmaDrug's cepharanthine programs in both COVID-19 and rare cancers'
PharmaDrug's Super Smart launches Slim MycoWeRx brand of functional mushrooms
It said MycoWe℞ Infinite will be positioned as a premium brand in a rapidly growing marketplace that is primarily occupied by high price, low potency functional mushroom products
PharmaDrug says experienced pharma analyst and executive David Kideckel is joining its board
Daniel Cohen, chairman and CEO of PharmaDrug, commented: "David's unique combination of experience in big pharma, biotech and investment banking ideally suits PharmaDrug as it increasingly shifts its focus to a biotech strategy"
PharmaDrug announces clinical research collaboration with Johns Hopkins University to evaluate DMT in a comparative clinical study
The clinical research collaboration builds upon its existing strategy of focusing on establishing a better understanding of the basic mechanisms by which DMT exerts its effects in the brain and elsewhere in the body
PharmaDrug and the Terasaki Institute to develop ocular delivery platform for DMT to treat eye diseases
The two groups will develop the platform to transmit tryptamine-based pharmaceuticals such as DMT to treat eye diseases like glaucoma, the second-leading cause of blindness in the world
PharmaDrug reveals study results showing cepharanthine significantly inhibits cancer cell growth in 20 different cancers
CEO Daniel Cohen told shareholders that the firm did not expect to see such significant growth inhibition in difficult-to-treat cancers
PharmaDrug to debut a new ticker symbol on the Canadian Securities Exchange in August
The pharmaceutical company announced it is changing its Canadian ticker symbol from ‘BUZZ’ to ‘PHRX’ to better align with its strategy
PharmaDrug reveals positive results from preclinical cepharanthine study in cancer showing heightened response in cell lines
Data from 35 of the 60 cancer cell lines were reported to PharmaDrug, with 11 cancer cell lines showing the heightened response
PharmaDrug advances product and clinical development of cepharanthine to treat infectious diseases including coronavirus
The company believes that its novel formulation of cepharanthine, PD-001 would be an ideal candidate to evaluate as a potential treatment for mild-to-moderate COVID-19
PharmaDrug launches Slim Winkel online retail platform in the Netherlands
The digital store will sell psilocybin truffles as well as functional mushrooms in the Netherlands, while the European market will have access to only the functional mushrooms
PharmaDrug says Super Smart division launches Slim Winkel-branded online retail platform in US with focus on functional mushrooms
Visitors to the Slim Winkel e-commerce site will be treated to informative blogs and educational tips that will allow them to easily integrate the mushrooms into their lifestyle
PharmaDrug inks supply deal for the production and sale of THC oil in Germany
The company said it will begin selling the THC product in Germany by September, one of several movers it is making to significantly increase its presence and volumes in the German medical cannabis market
PharmaDrug promotes Dr Paul Van Slyke to Chief Scientific Officer for whole group
Van Slyke previously served as the CSO on a consultancy basis of biotech and subsidiary Sairiyo Therapeutics, which PharmaDrug recently acquired
PharmaDrug begins preclinical studies of Cepharanthine formulation in a wide range of cancers
The study will look at the anti-cancer properties of the enteric-coated formulation of Cepharanthine known as PD-001 in a large panel of solid and liquid cancer cell types
PharmaDrug becomes first company to receive Orphan Drug Designation for DMT from the US FDA
The designation was granted to PharmaDrug’s subsidiary Sairiyo Therapeutics Inc and covers solid organ transplantation, which includes the liver, kidney, heart and lungs
PharmaDrug signs deal to begin manufacturing potential esophageal cancer and coronavirus treatment Cepharanthine
In connection with its recent acquisition of Sairiyo Therapeutics, the company has secured an exclusive license to develop and commercialize a novel oral formulation
PharmaDrug teams up with leading DMT researcher Jimo Borjigin at the University of Michigan in new study collaboration
Borjigin has been studying DMT since 2012 and published seminal research, including the discovery of DMT production in the pineal gland of live rats
PharmaDrug subsidiary adds drug repurposement expert Moshe Rogosnitzky to its scientific and clinical advisory board
Rogosnitzky leads Drug Rediscovery Group Ltd in Rehovot, Israel, which focuses on the repurposing of generic drugs
PharmaDrug welcomes top Memorial Sloan Kettering gastrointestinal oncologist Yelena Janjigian to its scientific and clinical advisory board
An international expert in cancers of the esophagus and stomach, Janjigian is currently leading several studies that could impact the standard of care for cancers in these fields
PharmaDrug files Orphan Drug Designation with US FDA for the use of DMT in kidney transplants
DMT has been shown to have anti-inflammatory properties and potentially mitigates ischemia-reperfusion injury caused by hypoxia, oxidative stress and inflammation in preclinical models of renal transplantation
PharmaDrug files Orphan Drug Designation application with the US Food and Drug Administration for use of N,N-Dimethyltryptamine (DMT) in the treatment of acute ischemic stroke patients
"With the submission of our orphan drug application to the FDA now complete we will move swiftly to accelerate the research and development of DMT for acute ischemic stroke," said Daniel Cohen, CEO of PharmaDrug
PharmaDrug appoints world-renowned chemist and neuroscientist Dr Steven Barker to its scientific advisory board for psychedelic pharmaceuticals
He will lead the R&D initiatives of N,N-Dimethyltryptamine (DMT) for mental health, neurological, and inflammatory disorders
Fast-paced PharmaDrug looks to create winning formula with cannabis, psychedelics and biotechnology
Not just that, the Canada-listed business has planted flags in Germany and the Netherlands
PharmaDrug inks supply agreement with a Canadian-based multinational cannabis company for EU-GMP certified medical cannabis
Under the supply agreement, the company's licensed German distributor, Pharmadrug Production GmbH will purchase branded medical cannabis from the supplier's German subsidiary
PharmaDrug completes previously announced acquisition of Sairiyo Therapeutics
"We are extremely excited to close the acquisition of Sairiyo and enter into a new phase for PharmaDrug. The acquisition helps complete PharmaDrug's business model by adding a vertical in research and development"
PharmaDrug finalizes deal to acquire biotechnology firm Sairiyo in all-stock deal worth C$7.5 million
Sairiyo’s lead drug candidate, Cepharanthine, is a repurposed and reformulated naturally derived compound being developed to treat rare forms of cancer